Halozyme Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 373
- Market Cap
- $8B
- Website
- http://www.halozyme.com
- Introduction
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and a...
52 Week Study of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents with Hypogonadism
- Conditions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 100
- Registration Number
- NCT06689085
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
- Conditions
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 14
- Registration Number
- NCT03662334
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 85
- Registration Number
- NCT03267940
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 492
- Registration Number
- NCT02715804
- Locations
- 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Baylor College of Medicine - Baylor Clinic, Houston, Texas, United States
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT02563548
- Locations
- 🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT02346370
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence (cCare), Fresno, California, United States
🇺🇸Moores UCSD Cancer Center, Clinical Trials Office, San Diego, California, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 456
- Registration Number
- NCT01848990
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Madison, Wisconsin, United States
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 279
- Registration Number
- NCT01839487
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Lahey Clinic, Burlington, Massachusetts, United States
Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT01572012
- Locations
- 🇺🇸
Icon Development Solutions, San Antonio, Texas, United States
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
- Conditions
- Interventions
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 25
- Registration Number
- NCT01526733
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States